All Stories

  1. Combining brain-penetrating and anticancer peptides into bivalent-branched peptides conserves brain targeting and improves activity in vitro
  2. Linker Design in Antibody-Drug Conjugates: Balancing Stability and Drug Release
  3. Comparative characterization of six teleost piscidins reveals distinct antimicrobial, antibiofilm and stability profiles
  4. Linker Design in Antibody-Drug Conjugates: Balancing Stability, Release and Resistance
  5. Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration
  6. Multivalent peptides for blood–brain barrier translocation, cell penetration and microRNA-21 inhibition in glioblastoma
  7. Antimigratory and Antiproliferative Effects of the Brain‐Targeted Peptide Conjugate PepH3‐vCPP2319 on Triple Negative Breast Cancer Cell Cultures
  8. PepH3-modified nanocarriers for delivery of therapeutics across the blood-brain barrier
  9. The Potential of Peptide-Based Inhibitors in Disrupting Protein–Protein Interactions for Targeted Cancer Therapy
  10. Optimizing magnetic hyperthermia for melanoma: the role of nanoparticle uptake inhibition
  11. vCPP2319 interacts with metastatic breast cancer extracellular vesicles (EVs) and transposes a human blood-brain barrier model
  12. Molecular determinants for brain targeting by peptides: a meta-analysis approach with experimental validation
  13. The use of a selective, nontoxic dual-acting peptide for breast cancer patients with brain metastasis
  14. Non-toxicity of Plant Candicidal Peptides for Mammalian Cell Lines and Galleria mellonella Model to Improving Selectivity for Clinical Use
  15. Quantitative Imaging of the Action of vCPP2319, an Antimicrobial Peptide from a Viral Scaffold, against Staphylococcus aureus Biofilms of a Clinical Isolate
  16. Panobinostat-loaded folate targeted liposomes as a promising drug delivery system for treatment of canine B-cell lymphoma
  17. Biological response and cell death signaling pathways modulated by tetrahydroisoquinoline-based aldoximes in human cells
  18. Structural and Biochemical Characterization of Three Antimicrobial Peptides from Capsicum annuum L. var. annuum Leaves for Anti-Candida Use
  19. Rabbit derived VL single-domains as promising scaffolds to generate antibody–drug conjugates
  20. Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors
  21. Posters
  22. Targeting Zika Virus with New Brain- and Placenta-Crossing Peptide–Porphyrin Conjugates
  23. The Use of Antibody-Antibiotic Conjugates to Fight Bacterial Infections
  24. The antimetastatic breast cancer activity of the viral protein‐derived peptide vCPP2319 as revealed by cellular biomechanics
  25. Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide
  26. Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening
  27. Conjugation of a Blood Brain Barrier Peptide Shuttle to an Fc Domain for Brain Delivery of Therapeutic Biomolecules
  28. Penetrating the Blood-Brain Barrier with New Peptide–Porphyrin Conjugates Having anti-HIV Activity
  29. Orally Active Peptide Vector Allows Using Cannabis to Fight Pain While Avoiding Side Effects
  30. Estimating peptide half‐life in serum from tunable, sequence‐related physicochemical properties
  31. Bioconjugate Supramolecular Pd2+ Metallacages Penetrate the Blood Brain Barrier In Vitro and In Vivo
  32. The Challenge of Peptide Proteolytic Stability Studies: Scarce Data, Difficult Readability, and the Need for Harmonization
  33. The Challenge of Peptide Proteolytic Stability Studies: Scarce Data, Difficult Readability, and the Need for Harmonization
  34. To What Extent Do Fluorophores Bias the Biological Activity of Peptides? A Practical Approach Using Membrane-Active Peptides as Models
  35. DPepH3, an Improved Peptide Shuttle for Receptor-independent Transport Across the Blood-Brain Barrier
  36. The Effect of Different Fluorophores on Fluorescence-Based Techniques
  37. Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?
  38. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition
  39. P545 Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognition
  40. Biologically active peptides linked to antibody fragments
  41. Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims
  42. SAT0046 TNF antagonist drug safety assessment by pharmacovigilance signaling and post-marketing adverse event reports
  43. Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles
  44. Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies